Filter documents

pdf icon

FSRH New Product Review: One size contraceptive diaphragm (Caya®) (August 2014)

File size: 240kb | Date: 1 August 2014 | New Product Reviews - PDF

Diaphragms are non-hormonal barrier methods of contraception that protect women against pregnancy by preventing sperm reaching the cervix. A single size contraceptive cap, FemCap, has been available since 2004, but until recently diaphragm products have been made in a range of sizes and designs. As a result women may have been required to try several types of diaphragm during the fitting process.

pdf icon

FSRH Clinical Standards for Risk Management Jul 2014

File size: 275kb | Date: 1 July 2014 | Clinical Standards - PDF

Risk Management is an approach to improving the quality and safety of health care by identifying circumstances that put patients and staff at risk and acting to prevent or control those risks.

pdf icon

FSRH Quality Standard Contraceptive Services

File size: 614kb | Date: 1 April 2014 | Clinical Standards - PDF

A quality contraceptive service is vital in giving women and men of all ages choice and control over their reproduction, and is key to avoiding unplanned pregnancies and planning families. Contraception is a highly cost-effective intervention, which plays an important public health role in improving the lives of individuals, families and communities.

pdf icon

FSRH Clinical Standard Supporting Doctors' Appriasal and Revalidation in SRH Apr 2014

File size: 761kb | Date: 1 April 2014 | Clinical Standards - PDF

With the introduction of the process of revalidation for doctors, appraisal has been standardised and this has been supported by the Medical Appraisal Guide, Model Appraisal Form Guidance for this has already been published by the Royal College of Obstetricians and Gynaecologists and Faculty of Sexual and Reproductive Healthcare outlining what supporting evidence should be provided at appraisal.

pdf icon

FSRH CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014)

File size: 59kb | Date: 1 March 2014 | Clinical Statements - PDF

Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.

pdf icon

FSRH CEU Statement: St Johns Wort and Hormonal Contraception (March 2014)

File size: 102kb | Date: 1 March 2014 | Clinical Statements - PDF

St Johns wort is a herbal product that is used for depressive symptoms and is known to have enzyme-inducing effects on cytochrome p450 enzymes. The MHRA statement highlights that in the last quarter of 2013, two ‘Yellow Card’ reports were received relating to unplanned pregnancies, in women with progestogen-only implants, suspected to be the result of an interaction with St John’s wort.